NorthStar Medical Radioisotopes Announces Launch of New Website to Showcase Company’s Expanding Commercial Success, Pipeline Progress and Plans for the Future

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is proud to announce the launch of its newly redesigned corporate website. The new site includes increased functionality and a number of enhancements. Expanded content includes latest product information, updates on NorthStar’s significant campus expansion, its growing partnerships and dynamic pipeline in therapeutic and SPECT radiopharmaceuticals, and the latest in career opportunities as the Company continues to grow and expand. NorthStar welcomes visitors to its new site at: www.northstarnm.com.

“We are very pleased to launch the new NorthStar corporate website that reflects our excitement and enthusiasm in working to provide global solutions for reliable medical radioisotope supply for patient health,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes. “We redesigned the website to provide details on NorthStar’s progress and expansion, our talented and experienced management team and employee base, our robust plans for the future and our commitment to patient health. This is an exciting time for NorthStar that warrants amplified communication and updates to our audiences. We believe there is no better way to share this information than with a highly relevant website that consistently provides streamlined, timely content.”

About NorthStar Medical Radioisotopes, LLC (NorthStar)

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals. Its first FDA-approved diagnostic imaging product is technetium-99m (Tc-99m), which is used in 40,000 patient imaging studies per day in the United States as standard of care to assess extent and severity of heart disease and cancer. Tc-99m is generated by NorthStar’s novel RadioGenix® System (technetium Tc-99m generator) which uses U.S.-produced, non-uranium based molybdenum-99 (Mo-99) as its source material. The Company is executing a well-defined plan to consistently increase the scale of Mo-99 production and to continuously improve efficiencies to meet anticipated increased demand. Therapeutic radioisotopes are increasingly important cancer treatment options, and NorthStar is developing commercial-scale production technologies to meet high demand for their use in ongoing clinical trials by multiple pharmaceutical companies. In addition, the Company is advancing a portfolio of other radiopharmaceuticals for use in therapeutic and diagnostic applications. For more information, visit: www.northstarnm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005198/en/